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Summary 26 
Setting 27 
The joint Médecins Sans Frontières/Ministry of Health multidrug-resistant tuberculosis 28 
(MDR-TB) programme; Karakalpakstan, Uzbekistan. 29 
Objective 30 
Uzbekistan has high rates of MDR-TB. We aimed to understand patients’ and prescribers’ 31 
attitudes to TB drug prescription, regulation, and drug-taking behaviour. 32 
Methods 33 
Participants (12 patients, 12 practitioners) were recruited purposively. Data were gathered 34 
qualitatively using field notes and in-depth interviews and analysed thematically. 35 
Findings 36 
Our analysis highlighted two main themes. First, shame and stigma were reported to increase 37 
the likelihood of self-treatment and incorrect use of TB drugs, most commonly at initial stages 38 
of illness. A health system failure to promote health information was perceived, leading to 39 
wrong diagnoses and inappropriate therapies. Motivated by shame, patients hid their 40 
condition by resorting to drug-treatment options outside the programme, compounding the 41 
risk of chaotic management and dissemination of erroneous information through lay 42 
networks. Second, positive influences on treatment were reported through patients, 43 
practitioners and peers working effectively together to deliver the correct information and 44 
support, which acted to normalise TB, reduce stigma and prevent misuse of TB drugs.  45 
Conclusion 46 
Effective case finding, patient support and community education strategies are essential. 47 
Patients, practitioners and peers working together can help reduce stigma and prevent 48 
misuse of TB drugs.  49 
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Introduction 50 
Multidrug-resistant tuberculosis (MDR-TB) describes TB resistant to the two most powerful 51 
first-line TB drugs: rifampicin and isoniazid. MDR-TB is an emerging global problem, 52 
affecting an estimated 3.5% of new TB cases and 20.5% of retreatment cases.1 Drug 53 
resistance is fuelled by many factors, including the quality of TB medications, poor 54 
adherence to treatment, ineffective treatment and retreatment regimens2,3 and poor 55 
hospital infection control practices. In addition, direct access to arbitrary use of TB drugs for 56 
patients through the private market has been implicated in treatment failure and 57 
development of drug resistance in high-burden countries.4 For instance, in Tbilisi, Georgia, 58 
TB drugs, including second-line agents used to treat MDR-TB, were widely available without 59 
prescription at pharmacies.5 Strategies to ensure effective drug management and supply 60 
form a major component of the World Health Organisation Stop TB Strategy.6 It has been 61 
concluded that policies regarding the sale and distribution of TB drugs should receive more 62 
attention in the global strategy to control drug resistance.7  63 
 64 
Médecins Sans Frontières (MSF) has treated MDR-TB in collaboration with the Ministry of 65 
Health (MoH) in Karakalpakstan, Uzbekistan since 2003. Within the MoH National 66 
Tuberculosis Programme, treatment for drug-resistant (DR) TB, at least in the intensive 67 
phase, is most commonly delivered on an inpatient basis. Reportedly, all parts of Uzbekistan 68 
now have access to rapid molecular diagnostics and WHO-recommended treatment 69 
regimens. In Karakalpakstan, treatment is delivered in the community, with all cases directly 70 
managed by the MoH. MSF provides technical support to clinicians, psychosocial support, 71 
side-effect medications, laboratory co-ordination and additional logistic support including 72 
infection control, nutritional support and assistance with adherence strategies. 73 
 74 
Uzbekistan has some of the highest reported rates of MDR-TB in the world, with 23% of new 75 
and 62% of retreatment TB cases identified as MDR.8 Treatment for TB outside the standard 76 
National Tuberculosis Programme is known to occur, despite a national drugs policy that 77 
prohibits the selling or use of TB drugs without prescription from a TB specialist clinician or 78 
clinic.9,10 We mapped all of the private and MoH-affiliated pharmacies in Karakalpakstan 79 
indicated over 400 such facilities, with evidence that in some that it was possible to 80 
 4 
 
purchase drugs used to treat sensitive TB without prescription - most commonly isoniazid, 81 
rifampicin and streptomycin.  82 
 83 
The Uzbekistan Government has acknowledged the need to improve the regulatory system 84 
for drug products and pharmaceutical activity.9 However, Uzbekistan already has effective 85 
regulation, both in terms of policy and practice, for narcotic and psychotropic drugs. These 86 
drugs, detailed in Government-compiled lists, can be sold only under a special licence. A 87 
monthly audit is conducted, under relevant law, of medications sold against prescriptions 88 
provided to pharmacies. The Government is currently upgrading the TB drug regulation 89 
system for quality control and state registration of drugs to meet the norms and standards 90 
of the European Union and WHO. For instance, regional branches of the National Agency for 91 
Regulation of Drug Products are being established to guarantee adequate quality control. 92 
 93 
With the present momentum for improvement of drug regulation in Uzbekistan, there is a 94 
need for better understanding of TB drug use. With the impending availability of new drugs 95 
for TB, it is essential that appropriate policies are formulated and implemented to prevent 96 
their misuse. While there is some awareness of the challenge of TB drug regulation within 97 
the MoH and the private sector, examination of local TB drug use from patient and 98 
practitioner perspectives is critical. In particular, understanding patient and practitioner 99 
beliefs, knowledge and behaviours is crucial in revising drug regulation policies.  100 
 101 
We conducted a qualitative study to assess current policy and practice for the regulation of 102 
TB drugs in order to understand the perceptions, behaviour and experience of patients and 103 
practitioners in Karakalpakstan related to the use of TB medication. We aimed to 104 
understand and conceptualize patients’ and prescribers’ attitudes to TB drug prescription, 105 
TB drug-taking behaviour and the problems of TB drug regulation in a high-burden MDR-TB 106 
context.  107 
 108 
Methods 109 
Research design 110 
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We used a flexible participatory technique in which data were gathered from patients and 111 
practitioners using in-depth interviews guided by topic-led questions as well as field notes. 112 
Interview questions were based on themes relevant to the study aims and a literature 113 
search of studies, laws, policies and audits related to TB drug use and the role of the private 114 
market. Following standard qualitative interview procedures, the order of questions was 115 
driven by the nature of participant answers, leading to modification of the wording of 116 
questions and the order in which they were asked during interviews. The primary 117 
investigator conducting the interviews was from outside the treatment programme. 118 
 119 
‘Fair dealing’, which searches for and represents participants’ views as dispassionately as 120 
possible and without moral judgement, was achieved by seeking a wide range of 121 
perspectives from specialised to general practitioners within the domain of caring for 122 
people with DR-TB.11 Attention to negative cases was pursued, meaning that contradictory 123 
or unexpected findings were actively sought and explored to ensure predominant themes 124 
were a true reflection of participant responses. 125 
 126 
Setting and sample  127 
The study was conducted in the joint MoH/MSF TB programme in 2012 in three 128 
administrative districts of Karakalpakstan: Nukus, Takhiatash and Hodjeley. Recruitment of 129 
24 participants (12 practitioners and 12 patients) relied on a programme manager within 130 
the country. Initial identification for recruitment was contingent on the inclusion criteria: 131 
new patients, patients who had completed treatment and chronic patients were eligible. TB 132 
specialists, non-specialist doctors and pharmacists working in the MoH, for MSF or the 133 
private system were included where possible.  134 
 135 
A snowball technique was used for recruiting practitioners and patients to increase the 136 
uptake of participants who were difficult to reach due to communication and time 137 
limitations for public engagement with the research. A project manager/gatekeeper 138 
approached participants with an information sheet that outlined the study. Three people 139 
refused to participate, due to unavailability or unwillingness (one patient, two 140 
practitioners). Another patient agreed to participate, but did not attend the appointment 141 
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and was unavailable thereafter. Purposive sampling enabled recruitment of individuals with 142 
sufficient knowledge and experience of the study topic to enable development of 143 
generalised information on processes and typical patterns of meanings. Practitioner 144 
participants were mainly physicians working in the TB sector (MSF and MoH), but also 145 
general practitioners in primary health care and one MoH pharmacist. Patient participants 146 
were all DR-TB patients who had been enrolled in the national TB programme managed by 147 
MoH, in some cases with MSF support. Although a relatively small number of participants 148 
were interviewed, data collection was stopped when no new information was being 149 
generated from additional interviews.12  150 
 151 
Data collection 152 
Informed consent was sought both before and at the time of the interview using an 153 
information sheet translated into the local language (Karakalpak) stating the purpose of the 154 
study and the voluntary nature of participation. Participants additionally gave written 155 
consent on the day of their interview. Interviews were audio recorded in a private space, 156 
usually at the health facility where the practitioner worked or where the patient currently or 157 
had previously attended. All interviews were conducted with an interpreter to translate 158 
questions and responses from English to the local language. The interpreter was briefed 159 
before and after each interview to ensure the highest quality of data extraction. All 160 
interviews lasted between 45 and 60 minutes. 161 
 162 
Although participants were able to stop their interview at any point, no-one chose to do 163 
this. Confidentiality was assured for all participants, with names of the respondents and all 164 
data referring to them being replaced by codes (D for physician, TBS for TB Specialist, PH for 165 
Pharmacist, GP for General Practitioner, and P for patient). Electronic data were password 166 
protected. 167 
 168 
Data analysis 169 
From the moment data were generated during the interviews the ’thinking and theorising’ 170 
of data analysis began.13 Data were managed initially through verbatim transcription of all 171 
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recorded conversational interviews. Silences and emotional cues (e.g. sighing, laughter) in 172 
the audio recording of the interview were noted.  173 
 174 
Open coding of interview transcripts allowed reviewing and re-reviewing of text line by line 175 
so that the ‘tagging’ of words, phrases or paragraphs emerged into codes, which were 176 
constantly compared and refined revealing the experiences of the participants rather than 177 
being externally imposed.14 The first author sorted codes and categories by interconnected 178 
themes or concepts13 and discussed these with the second author. Codes emerged 179 
inductively; themes and categories were drawn from respondents to make ‘implicit belief 180 
systems explicit in order to generate some theoretical insight’.15 The decision to perform 181 
manual rather than electronic coding was partly related to the relatively small sample size 182 
and also to the value of interacting with the data in a way that promoted continuous 183 
refinement of interpretations and deeper understanding.13  184 
 185 
Participant validation involved 10% of each participant’s coded interview transcript chosen 186 
at random being checked by them, to ensure that the researcher’s documentation and 187 
analysis were not disputed. Researcher reflexivity and awareness of the potential for 188 
’personal or intellectual biases’ were exercised16 together with use of field notes and 189 
relevant literature.  190 
 191 
Ethics 192 
Ethics approval was granted by the MSF Ethics Review Board and the Bioethics Commission 193 
of the Ministry of Health of the Republic of Uzbekistan.  194 
 195 
Results 196 
The response rate was 86%. Participant age ranged from 22 to 60 years, with equal numbers 197 
of men and women. Table 1 describes the characteristics of participants. 198 
 199 
We present the main findings by negative and positive influences on TB treatment. Both 200 
influences highlighted the likelihood of incorrect use of TB drugs and the potential to prevent 201 
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self-administration or poor management of TB. We illustrate our findings through 202 
participants’ quotes (Boxes 1 and 2). 203 
 204 
Negative influences on TB treatment 205 
Negative influences encompass the factors that increased the likelihood of self-treatment, 206 
incorrect use, and chaotic management of TB drugs. Key among these influences were shame 207 
and stigma, and incorrect lay knowledge. 208 
 209 
Shame and stigma 210 
The shame and stigma that patients felt in having TB was a major contributor to the risk of 211 
incorrect treatment. Nearly all participants, both professional and patient, referred to these 212 
concepts as incentives for people infected with TB to seek self-treatment in order to avoid 213 
disclosing their status (Box 1, quotes 1, 2). 214 
 215 
Feelings of shame and stigma were also found to lead to chaotic management of TB 216 
treatment by patients, general practitioners and more widely in primary care; a point 217 
stressed by patients and practitioners. Participants differentiated between self-medication 218 
of TB drugs and mismanagement of these drugs by doctors or radiologists working outside 219 
the official TB programme; however, all participants associated a lack of knowledge about 220 
effective treatment of TB with the chaotic management of patient care (Box 1, quote 3). For 221 
patients, poor management by practitioners was the predominant issue (Box 1, quote 4). Of 222 
note, where patients were already in the official treatment programme, interruption of 223 
treatment due to side effects or quality of care was not seen as a risk factor for seeking 224 
alternative TB drugs, especially where disillusionment from drug side effects was the main 225 
reason for a treatment break. Instead, the inclination at this stage was towards seeking 226 
traditional healing options such as ingestion of dog fat or remedies from traditional healers 227 
(Box 1, quote 5). 228 
 229 
Incorrect lay knowledge 230 
The second factor influencing patients’ tendency to seek treatment outside the TB control 231 
programme involved what could be termed as incorrect lay knowledge. Information conveyed 232 
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through a neighbour, relative or lay community network during collective events such as 233 
weddings or funerals was perceived by patients as instrumental in the proliferation of 234 
incorrect advice on treatment for TB. Such information was implicated in decisions to seek 235 
treatment outside the TB programme, especially where lay networks indicated a quicker 236 
treatment solution was available (Box 1, quotes 6, 7). 237 
 238 
Risk of self-medication was highest prior to referral or entry to the TB programme. While 239 
access to TB drugs was prevalent, common knowledge about drugs specifically used to treat 240 
tuberculosis resistant to first-line therapy was limited.  241 
 242 
In terms of common knowledge, most patient participants demonstrated familiarity with 243 
the drugs used to treat sensitive TB as opposed to TB resistant to first-line treatment (Box 1, 244 
quote 8). Doctor and patient participants referred to the easy availability of TB drugs as a 245 
factor contributing to self-medication (Box 1, quotes 9, 10). The availability of TB drugs 246 
outside the TB programme and incorrect lay knowledge about TB treatment, coupled with 247 
shame and stigma surrounding TB, have a bearing on developing policy towards regulation 248 
of TB drugs.  249 
 250 
Positive influences on TB treatment  251 
Positive influences on TB treatment highlight how the correct information and support, 252 
communicated between patients, practitioners and peers working together effectively, and 253 
with strong policy support, can contribute to increasing familiarity with TB. This strengthens 254 
beliefs in the treatment as a cure, reduces stigma, and prevents misuse of TB drugs. 255 
 256 
Knowledge and belief about successful treatment 257 
In terms of overcoming chaotic management of treatment, all respondents suggested 258 
knowledge of successful TB treatment to be a key factor. This was noted not only in terms of 259 
understanding the association between treatment and cure from a doctor-patient 260 
perspective, but also in the context of good communication between specialists and general 261 
practitioners contributing to better management of treatment regimens for TB (Box 2, quote 262 
1). All participants referred to entry to the TB programme as helping prevent self-medication. 263 
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Once a patient had entered the treatment programme, the availability of free drugs, 264 
perceived as high quality and giving good results, was a positive feature for all participants 265 
(Box 2, quote 2,3). Both patient and practitioner insights on the control of TB treatment 266 
described easy access to medicines and the supply of formal treatment as essential to 267 
stopping self-medication. 268 
 269 
Other predominant ideas from patients and practitioners were associated with treatment 270 
compliance and understanding the strength of the drugs used to treat DR-TB. Ways to ease 271 
the side effects of TB drugs described by patients were presented as means of enduring 272 
treatment, indicating that peer support can increase patient awareness of the importance of 273 
completing treatment (Box 2, quote 4). Seeing positive outcomes arise through treatment 274 
completion and cure strengthened patients’ belief in treatment. In particular, the relationship 275 
between knowledge, belief in treatment and communicating completion of treatment and 276 
cure was stressed. One patient highlighted the education that the programme could offer 277 
through ‘seeing’ the disease; for example, the value of seeing the X-ray used as part of 278 
diagnosis (Box 2, quote 5). 279 
 280 
Health practitioner, peer, and policy support 281 
All respondents stressed the value of communication and doctor-patient support as a 282 
safeguard against alternative hidden treatments. There was evidence that this patient-283 
centred approach built up the necessary confidence, trust and motivation for patients to 284 
continue with appropriate treatment regimens (Box 2, quote 6). Peer support, involving 285 
sharing knowledge, experience and encouragement, was presented as valuable and part of 286 
patient solidarity. Of note, this support was not reported to have reached the home; instead 287 
the place where treatment was carried out was conceptualised as the place of sanctity for 288 
patients (Box 2, quote 7). Peer support and patients’ drive to overcome the difficult treatment 289 
emerged as potentially able to normalise TB. These factors should be nurtured as key 290 
components in patient-centred care, alongside effective case finding, tailored treatment and 291 
adherence. 292 
 293 
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On the question of better administrative, institutional and legal controls over the regulation 294 
of TB drug use, political leadership toward directives for more stringent control for specific TB 295 
drugs was indicated (Box 2 quote 8). 296 
 297 
In relation to indicators for effective treatment, the predominant ideas and majority themes 298 
found in both patient and practitioner responses showed that patients were more likely to 299 
perceive treatment as effective if they were correctly educated about the merit of TB drugs 300 
and experienced the benefits of completion of treatment. This in turn was seen to endorse 301 
the value of the TB programme. Alongside the ‘test and treat’ health education message, 302 
‘complete and cure’ was seen as equally necessary.  303 
 304 
Discussion  305 
Patients reported misuse of TB drugs to be most likely at the initial stage of their sickness 306 
and treatment journey. Motivated by the shame of having TB and the inherent social 307 
stigma, patients chose to hide their condition by resorting to drug-treatment options 308 
outside the National TB Programme.17 Self-treatment appeared less likely once patients had 309 
engaged with the programme, underlining the need for a strong case-finding component in 310 
the TB treatment approach. Finding patients and initiating correct diagnosis and treatment 311 
is critical to preventing a default to self-treatment and for promoting a successful outcome. 312 
Interruption of treatment was not a risk factor for seeking alternative TB drugs, but did 313 
initiate the use of alternative traditional treatments. Chaotic management of TB care was 314 
reported to be connected to instances where the primary care practitioner was presented 315 
with cases they did not know how best to treat.  316 
 317 
The value of a treatment programme characterised by free, accessible and supportive patient-318 
centred care was evident as an important determinant for sustaining effective treatment. As 319 
previously reported through studies looking at patient-centred care as positive for effective 320 
treatment, our findings support focus on the patient as key to maintaining good treatment 321 
practice both for primary care doctors involved in the TB programme and patients engaged 322 
in taking effective TB treatment.18 Likewise, doctor-patient trust and support were deemed 323 
significant in preventing misuse of drugs and therefore contributed to adherence.19 In 324 
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particular, Fiscella et al established that physicians’ verbal behaviour during a doctor-patient 325 
encounter was associated with trust by both practitioners and patients.20 326 
 327 
As supported by a growing body of evidence,21 patients saw peer support and belief in 328 
treatment as vital components of the TB programme. The next challenge is to extend this 329 
support and the positive experience of TB treatment to the home and community 330 
environments. This effort should involve targeted community sensitisation and supervised 331 
home-based treatment where indicated,22,23 in particular where social gatherings enable the 332 
transmission of incorrect knowledge.24 333 
Knowledge about TB and treatment should be an important component of future drug 334 
regulation strategies.25 The effective dissemination of correct knowledge can catalyse 335 
change. It is apparent that poor knowledge and a sense that cure is difficult or that 336 
treatment can fail can lead to stigma and non-disclosure of infection.26 Therefore, the 337 
communication of correct knowledge and understanding between patients, between 338 
patients and their doctors, and between doctors is essential for uptake and completion of 339 
effective TB treatment.27. 340 
 341 
Knowledge of and access to drugs used to treat sensitive TB in the private market was 342 
confirmed as a result of pharmacy audit exercise and patient knowledge drawn from the in-343 
depth interviews. However, drugs used predominantly to treat TB resistant to first-line 344 
drugs were not as available or as well known by patients. Political leadership is an essential 345 
consideration of the new policy development towards successful TB drug control, especially 346 
in light of new drugs in the TB treatment pipeline.28 The Panel shows policy 347 
recommendations that we have drawn from our research. 348 
 349 
Limitations 350 
Due to some patients’ experience of the benefits of treatment, the potential for them to 351 
present only a very positive account has been considered in terms of objectivity from the 352 
standpoint of cure. However, patients’ potential to articulate and draw on life stories related 353 
to a general engagement with treatment was well suited to the aims of the research. While 354 
the response rate was good, it is acknowledged that participants approached may have been 355 
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those easier to access by programme staff. The reason for participant refusal was linked to 356 
time availability and general doubts about the research. Even though private practitioners 357 
were not interviewed, insights into private and public health practices were seen through the 358 
perspective of all interviewees.  359 
 360 
Participants may give responses that they think the researcher is hoping to hear; however, 361 
for this study, the researcher was sufficiently distanced from the programme to counter this 362 
effect. The study design could be seen as offering a unique chance for participants to 363 
express their views and tell their stories to an outsider who had no responsibility in the 364 
programme. As is characteristic of qualitative research, the data cannot be generalized to 365 
the population but transferability to other research findings can apply. 366 
 367 
Conclusions  368 
This study was stimulated by practitioners’ anecdotal evidence that misuse of TB drugs was 369 
prolific through self-medication and regimen mismanagement. Our findings highlight the 370 
risks for TB drug misuse and the opportunities for prevention and reinforce the need for 371 
political engagement with the public and private sector.  372 
 373 
Stigma and shame and the desire for patients to seek treatment elsewhere should be 374 
addressed by inclusion of case finding and community education strategies in programming. 375 
A patient-centred treatment approach to TB achieves this aim and is thus as important as 376 
the administrative regulation of drug treatment regimens. A decentralised treatment 377 
approach with stringent controls is the best solution for TB drug regulation. As first-line TB 378 
drugs are perceived as more misused than second-line drugs, stringent regulation of these 379 
drugs is a feasible and urgent next step. 380 
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Table 1: Participant characteristics 404 
Participant characteristic Number of participants 
General practitioner (GP) 2 
TB specialist (TBS) 9 
Pharmacist  1 
Drug-resistant TB patients  
- New patients 6 
- Chronic patients 4 
- Completed treatment 2 
 405 
  406 
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Box 1. Negative influences: Illustrative quotes from participants 407 
Shame, stigma and chaotic management 408 
D1 (TBS) – 1. Then we have stigma meaning that it is a very bad form stigma means not telling 409 
others you have TB or getting treatment somewhere.  410 
P11 – 2. There are for example people of higher social levels they don’t want to go to hospitals 411 
they prefer hidden treatment when they buy drugs at pharmacies they do it secretly.  412 
Chaotic management by practitioners and patients 413 
D7 (TBS) – 3. I visit polyclinics and show [the general practitioners] their mistakes; they still 414 
repeat them when I next visit them. It means, that people do not feel themselves responsible.  415 
P12 – 4. When I contacted a doctor he said I got a bit cold. This and that, it had adhered to 416 
your lungs, it is enough to take these and those injections, but I couldn’t get the full treatment.  417 
P7 – 5. People say to go to a sorceress. If they believe them they may do this or that. It easier 418 
than taking drugs, that’s why they prefer that way. People always seek easier ways. That’s 419 
why they stop the drugs and go to them.  420 
Incorrect knowledge 421 
D6 (TBS) – 6. And if we talk about those who self-medicate from pharmacy, they usually say 422 
“my neighbour had TB and I get the same treatment from them, or a relative had TB, or 423 
someone at home”.  424 
D1 (TBS) – 7. They take without prescription, because they go to some events like funerals, 425 
weddings, that time they may hear “I got cough, and tried this drug”. Says he/she got tubazide 426 
[proprietary name for isoniazid], isoniazid [TB drug used in standard regimen] and advises 427 
them to others. Do you get me? They gather together during these events. They say “I have 428 
cough”, “your cough is very bad”, “a man in a drugstore told me, advised me, I got this and 429 
got cured”.  430 
PH 10– 8. At pharmacies? Many drugstores sell ethambutol, rifampicin is easily available, 431 
isoniazid, and I think it’s only pyrazinamide which is not delivered.  432 
D10 (TBS) – 9. Yes, yes, yes, free availability sometimes they disappear for example 433 
pharmaceutical companies don’t have them sometimes it happens and it is difficult to find 434 
them in drugstores and their prices increase now they are available yes available.  435 
D4 (TBS) – 10. Well it’s up to the patient because if the patient says ”I will take I will find” he 436 
may do this.   437 
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Box 2. Positive influences: Illustrative quotes from participants 438 
Knowledge about successful treatment 439 
D1 (TBS) – 1. We should work together with GPs... We should make it better in polyclinics and 440 
work with, umm other specialist, neurologists, with surgeons.  441 
P5 – 2. I wake up in the morning, thank God that I am good, and recently we started adding 442 
words like “when I finish the programme I will be healthy”. We live with these thoughts, with 443 
the idea that the treatment will have good effect on us.  444 
P11 – 3. These drugs are very good! If you take them you will be cured, I believe in their power 445 
when they told me they would treat me …I agreed despite all the difficulties.  446 
P5 – 4. We see the results of the quality. We are getting better thanks to these drugs. 447 
We…ummm…how to say it…I…umm…we, women here are taking drugs together and …ummm 448 
we talk to each other having no secrets. 449 
P1 – 5. But I have a strong belief in these drugs, the quality, the strength; I saw a picture of my 450 
lung I got happy. I believe in the effect of these drugs. 451 
Health practitioner, peer and policy support 452 
D7 (TBS) – 6. A doctor should pay much attention and time to the patient; I mean patient 453 
should see that not only his family wants him to recover but doctors too. Only this kind of 454 
attitude may help get him cured … if a doctor loses a patient’s trust, patient will not give him 455 
even a chance to treat.  456 
P6- 7. There have been many of them having problems at home, when they don’t have peace 457 
at home, they can’t take them at home, I can easily be a friend to anyone – we take drugs 458 
together here.  459 
D5 (TBS) – 8. To prevent this… to stop selling, we need to add…include to our work the 460 
Ministry of Health, the Cabinet of ministers, tax committee, customs, Government. If the 461 
ministry, tax committee and customs agree to join you this will be successful, fines will be 462 
enough for others to stop selling.  463 
 18 
 
Panel: Policy recommendations  464 
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 Political influence should be exercised by the relevant Government Ministries and 
WHO for more stringent control for specific TB drugs. Engagement between the 
public and private sector for this purpose is essential.  
 A free, patient-centred TB treatment approach is equally important for effective 
regulation. 
 The system of drug regulation for narcotic and psychotropic drugs in Uzbekistan 
should be adapted for TB drugs, especially for those that are vital for the treatment 
of drug-resistant TB. 
 Effective case finding, community education and patient support strategies should 
be included in programming to diminish the problem of shame and the desire for 
patients to seek treatment elsewhere.  
 Development of training and education programmes aimed at increasing clear 
guidance to general health practitioners: i.e. doctors, pharmacists and radiologists.  
 Inclusion of peer support within national TB programme strategies to enhance 
shared experience of TB treatment and cure. 
 
TB drug taking practices and regulation 19 
 
19 
 
                                                                                                                                                                                    
6 WHO. The Stop TB Strategy. WHO. http://www.who.int/tb/strategy/stop_tb_strategy/en/ 
(accessed Feb 4, 2015). 
7 Paydar A, Mak A, Al Jahdali H, et al. Global survey of national tuberculosis drug policies. Int 
J Tuberc Lung Dis 2011; 15: 613–9. 
8 World Health Organization. Global tuberculosis report 2014. Geneva: World Health 
Organization, 2014. 
9 National Drug Policy, 1999. Republic of Uzbekistan. 
http://www.gov.uz/en/authorities/ministries/1303 (accessed Feb 19, 2015). 
10 Ministry of Healthcare of Uzbekistan. On Enhancement of the TB Service in the Republic 
of Uzbekistan. Article 6, Prikaz №160, April 3, 2003. 
11 Dingwall R. Don't mind him - he's from Barcelona: qualitative methods in health studies. 
In: Daly J, Mcdonald I, Willis E, eds. Researching health care. London: Routledge, 1992: 161-
175. 
12 Green J, Thorogood N. Qualitative Methods for Health Research. SAGE Publications, 2004. 
13 Basit TN. Manual or electronic? The role of coding in qualitative data analysis. Educ Res 
2003; 45: 143–54. 
14 Bradley EH, Curry LA, Devers KJ. Qualitative Data Analysis for Health Services Research: 
Developing Taxonomy, Themes, and Theory. Health Serv Res 2007; 42: 1758–72. 
15 Borgalti, S. 1996. Introduction to Grounded Theory. 
http://www.analytictech.com/mb870/introtogt.htm (accessed Feb 4, 2015). 
16 Mays N, Pope C. Assessing quality in qualitative research. BMJ 2000; 320: 50–2. 
17 Courtwright A, Turner A. 2010. Tuberculosis and stigmatisation: pathways and 
interventions. Public Health Reports. 125 (suppl 4) 34-42. 
18 Lewis CP, Newell JN. Improving tuberculosis care in low income countries – a qualitative 
study of patients' understanding of "patient support" in Nepal. BMC Public Health 2009; 
9:190.  
19 Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, et al. Patient Adherence to 
Tuberculosis Treatment: A Systematic Review of Qualitative Research. PLoS Med 2007; 4: 
e238. doi:10.1371/journal.pmed.0040238. 
20 Fiscella K. Patient Trust: Is It Related to Patient-Centered Behavior of Primary Care 
Physicians? Medical Care 2004; 42:11. 
21 Macq J, Torfoss T, Getahun H. Patient empowerment in tuberculosis control: reflecting on 
past documented experiences. Trop Med Int Health 2007; 12: 873–885. 
22 Dolinar RM, Kumar V, Coutu-Wakulczyk G, Rowe BH. Pilot study of a home-based asthma 
health education program. Patient Educ Couns 2000; 40:93-102. 
23 Roy A, Abubakar I, Chapman A, et al. A Controlled Trial of the Knowledge Impact of 
Tuberculosis Information Leaflets among Staff Supporting Substance Misusers: Pilot Study. 
PLoS ONE 2011; 6: e20875. 
24 Berkman LF, Glass T, Brissette I, Seeman TE. From Social Integration to Health: Durkheim 
in the New Millenium. Soc Sci Med 2000; 51:843-857. 
25 Fatiregun AA, Ojo AS, Bamgboye AE. Treatment outcomes among pulmonary tuberculosis 
patients at treatment centers in Ibadan, Nigeria. Ann Afr Med 2009; 8:100-104. 
26 Macq J, Solis A, Martinez G, Martiny P. Tackling tuberculosis patients' internalized social 
stigma through patient centred care: An intervention study in rural Nicaragua. BMC Public 
Health 2008; 8:154. 
 20 
 
                                                                                                                                                                                    
27 Wandwalo ER, Mørkve O. Knowledge of disease and treatment among tuberculosis 
patients in Mwanza, Tanzania. Int J Tuberc Lung Dis 2000; 4:11. 
28 Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary 
political leadership. Lancet Infect Dis 2013; 13:529-39. 
